Previous 10 | Next 10 |
UroGen Pharma (URGN) expects net product revenue from Jelmyto sales for Q2 ended June 30, 2021, to be ~$13M (consensus $10.46M).Operating expenses are anticipated to be in the range of $33M-$38M.Cash and equivalents as of June 30, 2021, are expected to be ~$129M. “Our strong, prelimina...
73% growth in net product revenue over 1Q 2021 to approximately $13.0 million in 2Q 2021 2Q 2021 operating expenses anticipated in the range of $33 to $38 million Full 2Q 2021 financial results and conference call to be reported on Wednesday, August 4, 2021 ...
UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 12:00pm Eas...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in June: Jefferies Virtual Healthcar...
UroGen Pharma Ltd. (URGN) Q1 2021 Earnings Conference Call May 13, 2021, 08:30 AM ET Company Participants Lee Roth - Burns McClellan Liz Barrett - President and CEO Jeff Bova - Chief Commercial Officer Mark Schoenberg - Chief Medical Officer Molly Henderson - CFO Conference Call Participants ...
Gainers: Reliance Global Group (RELI) +39%.InnSuites Hospitality Trust (IHT) +28%.Comstock Holding (CHCI) +19%.Moxian (MOXC) +17%.MultiPlan (MPLN) +16%.AMC Entertainment (AMC) +16%.ImmunoPrecise Antibodies (IPA) +16%.Verso (VRS) +15%.Farmer Bro (FARM) +14%.Flux Power (FLUX) +13...
Gainers: MultiPlan (MPLN) +17%, Trinity Biotech (TRIB) +15%, Acutus Medical (AFIB) +11%, Novan (NOVN) +8%, Salarius Pharmaceuticals (SLRX) +7%.Losers: Evoke Pharma (EVOK) -17%, Curis (CRIS) -16%, UroGen Pharma (URGN) -16%, Eargo (EAR...
UroGen Pharma (URGN): Q1 GAAP EPS of -$1.17 beats by $0.10.Revenue of $7.49M misses by $1.56M.Press Release For further details see: UroGen Pharma EPS beats by $0.10, misses on revenue
Jelmyto ® net product revenue of $7.5 million for the first quarter of 2021 New patient starts in March and April of 2021 increased 100% and 165%, respectively, compared to new patient starts in January 2021 Phase 3 ATLAS trial enrollment ongoing with new si...
Conference Call and Webcast Scheduled for Thursday, May 13, 2021 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...